• ICCVAM Activities Under the U.S. Strategic Roadmap (2MB)
• FDA/CDER Considerations on NAMs for Pharmaceutical Development (540KB)
• Qualification of In Vitro Alternatives for Biocompatibility Assessment of Medical Devices: Use of Medical Device Development Tools (MDDTs) (561KB)
• U.S. Army Combat Capabilities Development Command Chemical Biological Center (2MB)
• Reduction of Testing on Vertebrates Under the Amended Toxic Substances Control Act (278KB)
• Evaluation and Implementation of New Approach Methodologies for Evaluation of Pesticide Chemicals (699KB)
• Pesticides Invention to Market (517KB)
• Two Current Gaps for Incorporation of NAMs into Toxicity Testing and Risk Assessment (2MB)
• IQ MPS Affiliate Perspective on Characteristics and Requirements for New Approach Methodologies (NAMs) (4MB)

Contacts

Lingamanaidu V. Ravichandran, Ph.D.

Health Scientist Administrator

Tel 984-287-3309
[email protected]